摘要
目的观察吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌的临床效果及毒副反应。方法将108例晚期非小细胞肺癌患者随机分为观察组、对照组G及对照组N,其中,观察组患者给予吉西他滨联合长春瑞滨治疗,对照组G患者给予吉西他滨联合顺铂治疗,对照组N患者给予长春瑞滨联合顺铂治疗。治疗4个周期后,观察各组的临床疗效及毒副反应情况。结果经过4个周期的化疗后,可供评价疗效者共103例,其中,观察组35例,对照组G 34例,对照组N 34例。观察组与对照组的总缓解率及疾病缓解时间差异均无统计学意义(P>0.05);观察组中位生存时间显著长于对照组G和对照组N(P<0.05);观察组出现白细胞下降、血小板下降、红细胞下降、恶心、呕吐及脱发的发生率均明显低于对照组G和对照组N(P<0.05)。结论吉西他滨联合长春瑞滨是晚期非小细胞肺癌的有效姑息治疗方案,可显著延长患者的中位生存时间,小剂量联合应用两种药物可起到与大剂量吉西他滨或长春瑞滨单独应用相同的效果,且可明显降低血液系统及消化道系统不良反应。
Objective To observe the clinical efficacy and toxicity of gemcitabine combined with navelbine in treat- ment of advanced non-small cell lung cancer （NSCLC）. Methods 108 cases of patients with advanced NSCLC were randomly divided into observation group,control group G and control group N,while the observation group received gemcitabine combined with vinorelbine treatment,the control group G and control group N only received gemcitabine and navelbine respectively.The clinical efficacy and toxicity of each group after 4 cycles were observe. Results 103 cases were evaluated after 4 cycles,of which 35 cases of the observation group,34 cases of the control group G and 34 cases of the control group N.The overall response rate and remission time between the observation group and the con- trol group had no statistically significance （P〉0.05）;the median survival time of the observation group was significantly longer than that of the control group G and control group N with statistically significant （P〈0.05）.The rates of toxicity such as leukopenia,thrombocytopenia,decreased red blood cells,nausea,vomiting and alopecia of observation group were significantly lower than that of the control group G and control group N （P〈0.05）. Conclusion Gemcitabine combined with vinorelbine is an effective palliative treatment programs for advanced NSCLC significantly,which can significantly prolong the median survival time,with the low-dose combination of the two drugs can play the same effect with high- dose gemcitabine or navelbine alone,and can significantly reduce the blood system and digestive system adverse reac- tions.
出处
《中国当代医药》
2013年第32期84-85,87,共3页
China Modern Medicine
关键词
非小细胞肺癌
吉西他滨
长春瑞滨
联合治疗
Non-small cell lung cancer
Gemcitabine
Navelbine
Combination therapy
